From the Guidelines
Converting from Azstarys to Daytrana requires careful consideration, and the most recent evidence suggests starting with a Daytrana 10 mg/9-hour patch for patients previously on Azstarys 26.1/5.2 mg, a 15 mg patch for those on Azstarys 39.2/7.8 mg, or a 20 mg patch for those on Azstarys 52.3/10.4 mg 1. When switching from Azstarys (serdexmethylphenidate/dexmethylphenidate) to Daytrana (methylphenidate transdermal patch), it is essential to consider the different formulations and their effects on the body.
- Apply the Daytrana patch to clean, dry skin on the hip each morning, removing it 9 hours later.
- The patch may take 2 hours to start working, unlike Azstarys which works more quickly.
- Monitor for side effects including skin irritation at the application site, decreased appetite, sleep problems, and cardiovascular effects.
- Adjust the dose based on response after 1-2 weeks. During the transition, be aware that Daytrana delivers medication through the skin rather than orally, which may result in different absorption patterns and timing of effects compared to Azstarys 1. Some patients may need dose adjustments to achieve optimal symptom control with the new delivery system. The choice of medication and dosing regimen can significantly impact medication adherence, and once-daily dosing should generally be preferred over twice-daily dosing 1. It is crucial to regularly assess medication adherence and openly discuss potential issues in adherence to increase medication adherence as early as possible 1. Considering the potential advantages and disadvantages of different medications, stimulants like methylphenidate are generally recommended as first-line therapy, while non-stimulants like atomoxetine are recommended as second-line therapy 1. However, the approval statuses of individual medications and the specific guidelines for different countries or regions should be taken into account when making treatment decisions 1.
From the Research
Daytrana Conversion from Azstarys
There are no research papers to assist in answering this question, as the provided studies do not mention Daytrana conversion from Azstarys.
Available Information on ADHD Medications
- The studies provided discuss the efficacy and safety of various ADHD medications, including methylphenidate, amphetamine, and atomoxetine 2, 3, 4, 5.
- These medications have been shown to be effective in treating ADHD symptoms in children and adults, with varying degrees of efficacy and safety 2, 3, 4, 5.
- However, none of the studies mention Daytrana or Azstarys, or provide information on converting from one to the other.
Limitations of Available Research
- The available research focuses on the efficacy and safety of specific ADHD medications, but does not provide information on converting between different medications 2, 3, 4, 5.
- Further research is needed to investigate the safety and efficacy of converting from one ADHD medication to another, including Daytrana and Azstarys.